These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29191372)

  • 21. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
    Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
    Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
    [No Abstract]   [Full Text] [Related]  

  • 22. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
    Clavenna MJ; Turner JH; Samuelson M; Tanner SB; Duncavage J; Chandra RK
    Allergy Asthma Proc; 2016; 37(1):23-6. PubMed ID: 26831843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between allergen immunotherapy and omalizumab for treating asthma.
    Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
    Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.
    Mirra V; Montella S; Santamaria F
    BMC Pediatr; 2018 Feb; 18(1):73. PubMed ID: 29466963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of omalizumab on T lymphocyte function in inner-city children with asthma.
    Gruchalla RS; Sampson HA; Liu AH; Shreffler W; Wallace PK; Togias A; David G; Calatroni A; LeBeau P;
    Pediatr Allergy Immunol; 2016 May; 27(3):328-31. PubMed ID: 26573086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab: a treatment for severe asthma in real life?
    Briquet A; Chanez P
    Rev Port Pneumol (2006); 2015; 21(3):111-2. PubMed ID: 25943448
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
    Assayag M; Moshel S; Kohan M; Berkman N
    Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab as a Therapeutic Option for Nasal Polyposis in Moderate-to-Severe Persistent Allergic Asthma: Evidence From a Prospective Study in a Real-World Setting.
    Ruiz-Hornillos J; Rodríguez Jiménez B; Feliu Vila A; Moreno Fernández A; Hernández García MJ; Domínguez-Ortega J;
    J Investig Allergol Clin Immunol; 2020; 30(6):470-472. PubMed ID: 32490823
    [No Abstract]   [Full Text] [Related]  

  • 34. [Omalizumab: Beyond anti-IgE properties].
    Perotin JM; Barnig C
    Rev Mal Respir; 2017 Feb; 34(2):121-133. PubMed ID: 28189435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.
    Tadrous M; Khuu W; Lebovic G; Stanbrook MB; Martins D; Paterson JM; Mamdani MM; Juurlink DN; Gomes T
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):59-65.e2. PubMed ID: 28986124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
    Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
    Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
    Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
    Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
    Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
    Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.